pharma · Inflammatory Bowel Disease (IBD) · Melanoma · IRON
Disc Medicine
Disc Medicine is a pharma organization headquartered in Watertown, USA. It trades on NYSE under ticker IRON. Primary therapeutic focus areas include Inflammatory Bowel Disease (IBD), Melanoma, Parkinson's disease, Falcip
Company details
- Status
- Public
- HQ
- 321 Arsenal St., Suite 101, Watertown, Massachusetts 02472-5710, US
- Employees
- 165
- Programs
- 308
- Drugs
- 443
- Patents
- 706
NL79088.041.21
Phase 3 · small molecule · Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise)
NL79088.041.21 for Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise) is a Phase 3 program (small_molecule) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Internal code NL79088.041.21
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Disc Medicine
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise)
- Status
- active
- Trials
- 1